google_llm.py:169 DEBUG:
LLM Request:
-----------------------------------------------------------
System Instruction:
You are a medical expert explaining health topics to a regular person.

    Use the 'pubmed_search_articles' tool to find PMID's for research papers on the given topic using the following filters:
        "maxResults": 5,
        "sortBy": "pub_date",
        "filterByPublicationTypes": ["Review", "Journal Article"],

    Then, use the 'mcp_pubmed_server.pubmedFetchContents' tool to get the full text of the papers based on the PMIDs.

    Return the summarize the search results and include citations and a link to each paper used based on the PMIDs.
    

You are an agent. Your internal name is "research_paper_finder_agent".
-----------------------------------------------------------
Config:
{'tools': [{}]}
-----------------------------------------------------------
Contents:
{"parts":[{"text":"Summarize some relevant research papers about the best treatments for stage 4 prostate cancer?"}],"role":"user"}
{"parts":[{"function_call":{"args":{"sortBy":"pub_date","queryTerm":"stage 4 prostate cancer best treatments","filterByPublicationTypes":["Review","Journal Article"],"maxResults":5},"name":"pubmed_search_articles"}}],"role":"model"}
{"parts":[{"function_response":{"name":"pubmed_search_articles","response":{"content":[{"type":"text","text":"{\n  \"searchParameters\": {\n    \"queryTerm\": \"stage 4 prostate cancer best treatments\",\n    \"maxResults\": 5,\n    \"sortBy\": \"pub_date\",\n    \"filterByPublicationTypes\": [\n      \"Review\",\n      \"Journal Article\"\n    ],\n    \"fetchBriefSummaries\": 0\n  },\n  \"effectiveESearchTerm\": \"stage 4 prostate cancer best treatments AND (\\\"Review\\\"[Publication Type] OR \\\"Journal Article\\\"[Publication Type])\",\n  \"totalFound\": 130,\n  \"retrievedPmidCount\": 5,\n  \"pmids\": [\n    38920407,\n    38398155,\n    37418998,\n    36754722,\n    36725447\n  ],\n  \"briefSummaries\": [],\n  \"eSearchUrl\": \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=stage+4+prostate+cancer+best+treatments+AND+%28%22Review%22%5BPublication+Type%5D+OR+%22Journal+Article%22%5BPublication+Type%5D%29&retmax=5&sort=pub_date&usehistory=n\"\n}"}],"isError":false}}}],"role":"user"}
{"parts":[{"text":"Summarize some relevant research papers about the best treatments for stage 4 prostate cancer?"}],"role":"user"}
{"parts":[{"function_call":{"args":{"pmids":["38920407","38398155","37418998","36754722","36725447"]},"name":"pubmed_fetch_contents"}}],"role":"model"}
{"parts":[{"function_response":{"name":"pubmed_fetch_contents","response":{"content":[{"type":"text","text":"{\"requestedPmids\":[\"38920407\",\"38398155\",\"37418998\",\"36754722\",\"36725447\"],\"articles\":[{\"pmid\":\"38920407\",\"title\":\"A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).\",\"abstractText\":\"UNLABELLED: We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle) in patients with solid tumor malignancies harboring a pathogenic SETD2 mutation. The primary endpoint was the objective response rate. Correlative assays evaluated the loss of H3K36me3 by IHC, a downstream consequence of SETD2 loss, in archival tumor tissue. Eighteen patients were enrolled (9/cohort). The median age was 60 years (range 45-74). The median duration of treatment was 1.28 months (range 0-24+). No objective responses were observed in either cohort; accrual was halted following stage 1. Minor tumor regressions were observed in 4/18 (22%) evaluable patients. Stable disease (SD) was the best overall response in 10/18 (56%) patients, including three patients with SD > 4 months. One patient with ccRCC remains on treatment for >24 months. The most common adverse events of any grade were nausea (59%), anemia (41%), diarrhea (41%), and neutropenia (41%). Nine patients (50%) experienced a Grade &#x2265;3 adverse event. Of eight evaluable archival tissue samples, six (75%) had a loss of H3K36me3 by IHC. Adavosertib failed to exhibit objective responses in SETD2-altered ccRCC and other solid tumor malignancies although prolonged SD was observed in a subset of patients. Combination approaches may yield greater depth of tumor response.\\n\\nSIGNIFICANCE: WEE1 inhibition with adavosertib monotherapy demonstrated limited clinical activity in patients with SETD2-altered solid tumors despite compelling preclinical data indicating a synthetic lethal effect, which did not translate into robust tumor regression. Loss of the H3K36me3 trimethylation mark caused by SETD2-deficiency was confirmed in the majority of evaluable tumors. A subset of patients derived clinical benefit as manifested by minor tumor regressions and prolonged SD.\",\"authors\":[{\"lastName\":\"Maldonado\",\"firstName\":\"Edward\",\"initials\":\"E\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"Rathmell\",\"firstName\":\"W Kimryn\",\"initials\":\"WK\",\"affiliation\":\"Vanderbilt University Medical Center, Nashville, Tennessee.\"},{\"lastName\":\"Shapiro\",\"firstName\":\"Geoffrey I\",\"initials\":\"GI\",\"affiliation\":\"Dana-Farber Cancer Institute, Boston, Massachusetts.\"},{\"lastName\":\"Takebe\",\"firstName\":\"Naoko\",\"initials\":\"N\",\"affiliation\":\"National Cancer Institute, Bethesda, Maryland.\"},{\"lastName\":\"Rodon\",\"firstName\":\"Jordi\",\"initials\":\"J\",\"affiliation\":\"Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, Texas.\"},{\"lastName\":\"Mahalingam\",\"firstName\":\"Devalingam\",\"initials\":\"D\",\"affiliation\":\"Northwestern University, Evanston, Illinois.\"},{\"lastName\":\"Trikalinos\",\"firstName\":\"Nikolaos A\",\"initials\":\"NA\",\"affiliation\":\"Washington University St. Louis, St. Louis, Missouri.\"},{\"lastName\":\"Kalebasty\",\"firstName\":\"Arash R\",\"initials\":\"AR\",\"affiliation\":\"University of California, Irvine, Irvine, California.\"},{\"lastName\":\"Parikh\",\"firstName\":\"Mamta\",\"initials\":\"M\",\"affiliation\":\"University of California, Davis, Davis, California.\"},{\"lastName\":\"Boerner\",\"firstName\":\"Scott A\",\"initials\":\"SA\",\"affiliation\":\"Yale University, New Haven, Connecticut.\"},{\"lastName\":\"Balido\",\"firstName\":\"Celene\",\"initials\":\"C\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"Krings\",\"firstName\":\"Gregor\",\"initials\":\"G\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"Burns\",\"firstName\":\"Timothy F\",\"initials\":\"TF\",\"affiliation\":\"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.\"},{\"lastName\":\"Bergsland\",\"firstName\":\"Emily K\",\"initials\":\"EK\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"Munster\",\"firstName\":\"Pamela N\",\"initials\":\"PN\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"Ashworth\",\"firstName\":\"Alan\",\"initials\":\"A\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"},{\"lastName\":\"LoRusso\",\"firstName\":\"Patricia\",\"initials\":\"P\",\"affiliation\":\"Yale University, New Haven, Connecticut.\"},{\"lastName\":\"Aggarwal\",\"firstName\":\"Rahul R\",\"initials\":\"RR\",\"affiliation\":\"University of California, San Francisco, San Francisco, California.\"}],\"journalInfo\":{\"title\":\"Cancer research communications\",\"isoAbbreviation\":\"Cancer Res Commun\",\"volume\":\"4\",\"issue\":\"7\",\"pages\":\"1793-1801\",\"publicationDate\":{\"year\":\"2024\",\"month\":\"Jul\",\"day\":\"1\"}},\"publicationTypes\":[\"Journal Article\",\"Clinical Trial, Phase II\",\"Research Support, N.I.H., Extramural\",\"Research Support, Non-U.S. Gov't\"],\"doi\":\"10.1158/2767-9764.CRC-24-0213\",\"meshTerms\":[{\"descriptorName\":\"Humans\",\"descriptorUi\":\"D006801\",\"isMajorTopic\":false},{\"descriptorName\":\"Middle Aged\",\"descriptorUi\":\"D008875\",\"isMajorTopic\":false},{\"descriptorName\":\"Histone-Lysine N-Methyltransferase\",\"descriptorUi\":\"D011495\",\"qualifierName\":\"genetics\",\"qualifierUi\":\"Q000235\",\"isMajorTopic\":true},{\"descriptorName\":\"Male\",\"descriptorUi\":\"D008297\",\"isMajorTopic\":false},{\"descriptorName\":\"Aged\",\"descriptorUi\":\"D000368\",\"isMajorTopic\":false},{\"descriptorName\":\"Female\",\"descriptorUi\":\"D005260\",\"isMajorTopic\":false},{\"descriptorName\":\"Protein-Tyrosine Kinases\",\"descriptorUi\":\"D011505\",\"qualifierName\":\"antagonists & inhibitors\",\"qualifierUi\":\"Q000037\",\"isMajorTopic\":true},{\"descriptorName\":\"Cell Cycle Proteins\",\"descriptorUi\":\"D018797\",\"qualifierName\":\"genetics\",\"qualifierUi\":\"Q000235\",\"isMajorTopic\":true},{\"descriptorName\":\"Pyrazoles\",\"descriptorUi\":\"D011720\",\"qualifierName\":\"therapeutic use\",\"qualifierUi\":\"Q000627\",\"isMajorTopic\":true},{\"descriptorName\":\"Neoplasms\",\"descriptorUi\":\"D009369\",\"qualifierName\":\"drug therapy\",\"qualifierUi\":\"Q000188\",\"isMajorTopic\":false},{\"descriptorName\":\"Carcinoma, Renal Cell\",\"descriptorUi\":\"D002292\",\"qualifierName\":\"drug therapy\",\"qualifierUi\":\"Q000188\",\"isMajorTopic\":false},{\"descriptorName\":\"Kidney Neoplasms\",\"descriptorUi\":\"D007680\",\"qualifierName\":\"drug therapy\",\"qualifierUi\":\"Q000188\",\"isMajorTopic\":false},{\"descriptorName\":\"Pyrimidinones\",\"descriptorUi\":\"D011744\",\"qualifierName\":\"therapeutic use\",\"qualifierUi\":\"Q000627\",\"isMajorTopic\":false},{\"descriptorName\":\"Mutation\",\"descriptorUi\":\"D009154\",\"isMajorTopic\":false}]},{\"pmid\":\"38398155\",\"title\":\"How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy.\",\"abstractText\":\"Biochemical recurrence (BCR) after primary treatments for prostate cancer (PC) is an extremely heterogeneous phase and at least a stratification into low- and high-risk cases for early progression in metastatic disease is necessary. At present, PSA-DT represents the best parameter to define low- and high-risk BCR PC, but real precision medicine is strongly suggested to define tailored management for patients with BCR. Before defining management, it is necessary to exclude the presence of low-volume metastasis associated with PSA progression using new-generation imaging, preferably with PSMA PET/CT. Low-risk BCR cases should be actively observed without early systemic therapies. Early treatment of low-risk BCR with continuous androgen deprivation therapy (ADT) can produce disadvantages such as the development of castration resistance before the appearance of metastases (non-metastatic castration-resistant PC). Patients with high-risk BCR benefit from early systemic therapy. Even with overall survival (OS) as the primary treatment endpoint, metastasis-free survival (MFS) should be used as a surrogate endpoint in clinical trials, especially in long survival stages of the disease. The EMBARK study has greatly influenced the management of high-risk BCR, by introducing the concept of anticipation and intensification through the use of androgen receptor signaling inhibitors (ARSIs) and ADT combination therapy. In high-risk (PSA-DT &#x2264; 9 months) BCR cases, the combination of enzalutamide with leuprolide significantly improves MFS when compared to leuprolide alone, maintaining an unchanged quality of life in the asymptomatic phase of the disease. The possibility of using ARSIs alone in this early disease setting is suggested by the EMBARK study (arm with enzalutamide alone) with less evidence than with the intensification of the combination therapy. Continued use versus discontinuation of enzalutamide plus leuprolide intensified therapy upon reaching undetectable PSA levels needs to be better defined with further analysis. Real-world analysis must verify the significant results obtained in the context of a phase 3 study.\",\"authors\":[{\"lastName\":\"Sciarra\",\"firstName\":\"Alessandro\",\"initials\":\"A\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Santarelli\",\"firstName\":\"Valerio\",\"initials\":\"V\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Salciccia\",\"firstName\":\"Stefano\",\"initials\":\"S\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Moriconi\",\"firstName\":\"Martina\",\"initials\":\"M\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Basile\",\"firstName\":\"Greta\",\"initials\":\"G\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Santodirocco\",\"firstName\":\"Loreonzo\",\"initials\":\"L\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Carino\",\"firstName\":\"Dalila\",\"initials\":\"D\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Frisenda\",\"firstName\":\"Marco\",\"initials\":\"M\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Di Pierro\",\"firstName\":\"Giovanni\",\"initials\":\"G\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Del Giudice\",\"firstName\":\"Francesco\",\"initials\":\"F\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Gentilucci\",\"firstName\":\"Alessandro\",\"initials\":\"A\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"},{\"lastName\":\"Bevilacqua\",\"firstName\":\"Giulio\",\"initials\":\"G\",\"affiliation\":\"Department Materno Infantile e Scienze Urologiche, Sapienza University, Viale Policlinico 155, 00161 Rome, Italy.\"}],\"journalInfo\":{\"title\":\"Cancers\",\"isoAbbreviation\":\"Cancers (Basel)\",\"volume\":\"16\",\"issue\":\"4\",\"pages\":\"\",\"publicationDate\":{\"year\":\"2024\",\"month\":\"Feb\",\"day\":\"13\"}},\"publicationTypes\":[\"Journal Article\",\"Review\"],\"doi\":\"10.3390/cancers16040764\",\"articleDates\":[{\"dateType\":\"Electronic\",\"year\":\"2024\",\"month\":\"2\",\"day\":\"13\"}]},{\"pmid\":\"37418998\",\"title\":\"Advances in high-risk localized prostate cancer: Staging and management.\",\"abstractText\":\"Nearly 15% of individuals with localized prostate cancer are identified as high risk for recurrence and progression of the disease, which is why the correct staging is vital for the definition of correct treatment-also developing novel therapeutic strategies to find a balance between getting better outcomes without sacrificing the quality of life (QoL). In this narrative review, we introduced the current standards of staging and primary treatment of high-risk localized prostate cancer (PCa), based on international guidelines and arguments in the debate, under the light of the most recent literature. It brings essential tools such as PSMA PET/CT and different nomograms (Briganti. MSKCC, Gandaglia) for accurate staging and selecting wisely the definitive therapy. Even though there is a broad discussion over the best local treatment in curative-intent treatment, it looks more important to define which patient profile would adapt correctly to every different treatment, highlighting the benefits and superior outcomes with multimodal treatment.\",\"authors\":[{\"lastName\":\"Reina\",\"firstName\":\"Yeison\",\"initials\":\"Y\",\"affiliation\":\"Division of Urology, Hospital Universitario del Valle, Cali, Colombia; UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia.\"},{\"lastName\":\"Villaquir&#xe1;n\",\"firstName\":\"Catalina\",\"initials\":\"C\",\"affiliation\":\"Division of Urologic Oncology, Hospital Universitario San Ignacio, Bogota, Colombia.\"},{\"lastName\":\"Garc&#xed;a-Perdomo\",\"firstName\":\"Herney Andr&#xe9;s\",\"initials\":\"HA\",\"affiliation\":\"UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia; Division of Urology/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali, Colombia. Electronic address: herney.garcia@correounivalle.edu.co.\"}],\"journalInfo\":{\"title\":\"Current problems in cancer\",\"isoAbbreviation\":\"Curr Probl Cancer\",\"volume\":\"47\",\"issue\":\"4\",\"pages\":\"100993\",\"publicationDate\":{\"year\":\"2023\",\"month\":\"Aug\"}},\"publicationTypes\":[\"Journal Article\",\"Review\"],\"doi\":\"10.1016/j.currproblcancer.2023.100993\",\"articleDates\":[{\"dateType\":\"Electronic\",\"year\":\"2023\",\"month\":\"7\",\"day\":\"4\"}],\"meshTerms\":[{\"descriptorName\":\"Male\",\"descriptorUi\":\"D008297\",\"isMajorTopic\":false},{\"descriptorName\":\"Humans\",\"descriptorUi\":\"D006801\",\"isMajorTopic\":false},{\"descriptorName\":\"Positron Emission Tomography Computed Tomography\",\"descriptorUi\":\"D000072078\",\"isMajorTopic\":true},{\"descriptorName\":\"Quality of Life\",\"descriptorUi\":\"D011788\",\"isMajorTopic\":false},{\"descriptorName\":\"Prostatic Neoplasms\",\"descriptorUi\":\"D011471\",\"qualifierName\":\"diagnosis\",\"qualifierUi\":\"Q000175\",\"isMajorTopic\":true},{\"descriptorName\":\"Nomograms\",\"descriptorUi\":\"D049451\",\"isMajorTopic\":false},{\"descriptorName\":\"Neoplasm Staging\",\"descriptorUi\":\"D009367\",\"isMajorTopic\":false}]},{\"pmid\":\"36754722\",\"title\":\"The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.\",\"abstractText\":\"BACKGROUND: There is no consensus on the best local salvage treatment for prostate cancer recurrence after primary external beam radiotherapy. Prospective data on stereotactic body radiation therapy (SBRT) are very scarce.\\n\\nOBJECTIVE: To determine the optimal dose regimen for salvage SBRT.\\n\\nDESIGN, SETTING, AND PARTICIPANTS: The present report concerns the phase 1 part of the GETUG-AFU 31 multicenter open-label study. The main inclusion criteria were histologically proven biochemical recurrence, clinical stage T1-T2 upon relapse, multiparametric magnetic resonance imaging data, prostate-specific antigen (PSA) level &#x2264;10 ng/ml prior to salvage SBRT, PSA doubling time >10 mo, and an International Prostate Symptom Score of &#x2264;12.\\n\\nINTERVENTION: Five or six fractions of 6 Gy were delivered using focal SBRT.\\n\\nOUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Dose-limiting toxicity (DLT) was defined as grade &#x2265;3 gastrointestinal or genitourinary tract toxicity, or any grade 4 toxicity (according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03) occurring in the first 18 wk following treatment initiation. A time-to-event continual reassessment method was used to select the dose regimen.\\n\\nRESULTS AND LIMITATIONS: Twenty-one patients were treated (median [interquartile range] age: 76.8 yr [72.2-80.8]), including 12 at 6 &#xd7; 6 dose level. No DLT was observed. The acute grade 2 genitourinary tract toxicity rate was 19%. With a median follow-up of 12.3 mo, the estimated cumulative incidence of late grade 2 genitourinary toxicity was 41.2% (95% confidence interval: 18.1-63.1%). No grade >2 genitourinary toxicity and no grade &#x2265;2 gastrointestinal toxicity were reported. All treated patients were alive and relapse free at the last follow-up.\\n\\nCONCLUSIONS: A 6 &#xd7; 6 Gy dose regimen was selected for our phase 2 study of salvage SBRT. With a short follow-up period, the level of toxicity appears to be acceptable.\\n\\nPATIENT SUMMARY: There is no consensus on the best local treatment for patients with local relapse after radiotherapy for prostate cancer. Prospective data are very scarce. Our early phase trial allowed us to recommend six fractions of 6 Gy using high-precision radiotherapy for further studies.\",\"authors\":[{\"lastName\":\"Pasquier\",\"firstName\":\"David\",\"initials\":\"D\",\"affiliation\":\"Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; CRIStAL UMR CNRS 9189, Lille University, Lille, France. Electronic address: d-pasquier@o-lambret.fr.\"},{\"lastName\":\"Lacornerie\",\"firstName\":\"Thomas\",\"initials\":\"T\",\"affiliation\":\"D&#xe9;partement de Physique M&#xe9;dicale, Centre Oscar Lambret, Lille, France.\"},{\"lastName\":\"Supiot\",\"firstName\":\"St&#xe9;phane\",\"initials\":\"S\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Institut de Canc&#xe9;rologie de l'Ouest-Site Ren&#xe9; Gauducheau, Saint-Herblain, France.\"},{\"lastName\":\"Pommier\",\"firstName\":\"Pascal\",\"initials\":\"P\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Centre L&#xe9;on B&#xe9;rard, Lyon, France.\"},{\"lastName\":\"Quivrin\",\"firstName\":\"Magali\",\"initials\":\"M\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Centre Georges Fran&#xe7;ois Leclerc, Dijon, France.\"},{\"lastName\":\"Simon\",\"firstName\":\"Jean-Marc\",\"initials\":\"JM\",\"affiliation\":\"Service d'Oncologie Radioth&#xe9;rapie, Assistance Publique-H&#xf4;pitaux de Paris (APHP), H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Sorbonne Universit&#xe9;, Paris, France.\"},{\"lastName\":\"Loos\",\"firstName\":\"Genevi&#xe8;ve\",\"initials\":\"G\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Centre Jean Perrin, Clermont-Ferrand, France.\"},{\"lastName\":\"Meyer\",\"firstName\":\"Emmanuel\",\"initials\":\"E\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Centre Fran&#xe7;ois Baclesse, Caen, France.\"},{\"lastName\":\"Calais\",\"firstName\":\"Gilles\",\"initials\":\"G\",\"affiliation\":\"D&#xe9;partement d'Oncologie et de Radioth&#xe9;rapie, CHRU Tours, France.\"},{\"lastName\":\"Peiffert\",\"firstName\":\"Didier\",\"initials\":\"D\",\"affiliation\":\"D&#xe9;partement de Radioth&#xe9;rapie, Institut de Canc&#xe9;rologie de Lorraine, Vand&#x153;uvre-l&#xe8;s-Nancy, France.\"},{\"lastName\":\"Vandendorpe\",\"firstName\":\"Benjamin\",\"initials\":\"B\",\"affiliation\":\"Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.\"},{\"lastName\":\"Aymes\",\"firstName\":\"Estelle\",\"initials\":\"E\",\"affiliation\":\"D&#xe9;partement de Biostatistiques, Centre Oscar Lambret, Lille, France.\"},{\"lastName\":\"Leguillette\",\"firstName\":\"Cl&#xe9;mence\",\"initials\":\"C\",\"affiliation\":\"D&#xe9;partement de Biostatistiques, Centre Oscar Lambret, Lille, France.\"},{\"lastName\":\"Brihoum\",\"firstName\":\"Meryem\",\"initials\":\"M\",\"affiliation\":\"Unicancer, Recherche et D&#xe9;veloppement, Paris, France.\"},{\"lastName\":\"Nenan\",\"firstName\":\"Soazig\",\"initials\":\"S\",\"affiliation\":\"Unicancer, Recherche et D&#xe9;veloppement, Paris, France.\"},{\"lastName\":\"Cormier\",\"firstName\":\"Luc\",\"initials\":\"L\",\"affiliation\":\"Service d'urologie, CHU Besan&#xe7;on, France.\"},{\"lastName\":\"Le Deley\",\"firstName\":\"Marie-C&#xe9;cile\",\"initials\":\"MC\",\"affiliation\":\"D&#xe9;partement de Biostatistiques, Centre Oscar Lambret, Lille, France.\"},{\"lastName\":\"Lartigau\",\"firstName\":\"Eric F\",\"initials\":\"EF\",\"affiliation\":\"Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; CRIStAL UMR CNRS 9189, Lille University, Lille, France.\"}],\"journalInfo\":{\"title\":\"European urology oncology\",\"isoAbbreviation\":\"Eur Urol Oncol\",\"volume\":\"6\",\"issue\":\"4\",\"pages\":\"399-405\",\"publicationDate\":{\"year\":\"2023\",\"month\":\"Aug\"}},\"publicationTypes\":[\"Multicenter Study\",\"Clinical Trial, Phase I\",\"Journal Article\",\"Research Support, Non-U.S. Gov't\"],\"doi\":\"10.1016/j.euo.2023.01.009\",\"articleDates\":[{\"dateType\":\"Electronic\",\"year\":\"2023\",\"month\":\"2\",\"day\":\"7\"}],\"meshTerms\":[{\"descriptorName\":\"Male\",\"descriptorUi\":\"D008297\",\"isMajorTopic\":false},{\"descriptorName\":\"Humans\",\"descriptorUi\":\"D006801\",\"isMajorTopic\":false},{\"descriptorName\":\"Aged\",\"descriptorUi\":\"D000368\",\"isMajorTopic\":false},{\"descriptorName\":\"Radiosurgery\",\"descriptorUi\":\"D016634\",\"qualifierName\":\"adverse effects\",\"qualifierUi\":\"Q000009\",\"isMajorTopic\":true},{\"descriptorName\":\"Prostate-Specific Antigen\",\"descriptorUi\":\"D017430\",\"isMajorTopic\":false},{\"descriptorName\":\"Neoplasm Recurrence, Local\",\"descriptorUi\":\"D009364\",\"qualifierName\":\"radiotherapy\",\"qualifierUi\":\"Q000532\",\"isMajorTopic\":false},{\"descriptorName\":\"Prospective Studies\",\"descriptorUi\":\"D011446\",\"isMajorTopic\":false},{\"descriptorName\":\"Prostatic Neoplasms\",\"descriptorUi\":\"D011471\",\"qualifierName\":\"pathology\",\"qualifierUi\":\"Q000473\",\"isMajorTopic\":true}]},{\"pmid\":\"36725447\",\"title\":\"Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy.\",\"abstractText\":\"The pathological grade of prostate cancer is the strongest predictor of recurrence. It is unclear whether the better predictor is the composite of all carcinomas within the prostate, or the highest grade lesion (index). The purpose of this study was to determine whether composite or index grade group better predicts biochemical recurrence (BCR). We undertook a retrospective analysis from a prospective institutional cohort study of men who underwent radical prostatectomy for localised prostate cancer between 2009 and 2020, in which an index and composite grade group was reported. The index grade in this study was defined as the highest grade of any tumour, usually with the highest stage, regardless of volume. Multivariate analysis and Kaplan-Meier plots were utilised. A total of 2024 men underwent radical prostatectomy during the study period; we analysed 1605 with composite grade group 2 or 3 prostate cancer. Median preoperative prostate specific antigen (PSA) was 5.9 ng/L, mean follow up was 56.8 months, 54% were pT2, 76% had multifocal disease and 16% had discordant index and composite grades. Patients with discordant index grade group had a higher risk of BCR [hazard ratio (HR) 2.22, p<0.0001]. The prevalence of BCR in the discordant group was higher at 1, 3, 5 and 7 years (4.7% vs 8.9%, 8.3% vs 18.1%, 14.5% vs 28.8% and 22.5% vs 49.5%, respectively). In cases of discordance, a higher index grade group is associated with increased rates of BCR after radical prostatectomy. Index rather than composite grade group should be used to counsel men post-operatively regarding prognosis and follow-up.\",\"authors\":[{\"lastName\":\"Best\",\"firstName\":\"Oliver\",\"initials\":\"O\",\"affiliation\":\"Department of Urology, St George Hospital, Kogarah, NSW, Australia; Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia.\"},{\"lastName\":\"Canagasingham\",\"firstName\":\"Ashan\",\"initials\":\"A\",\"affiliation\":\"Department of Urology, St George Hospital, Kogarah, NSW, Australia; Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia. Electronic address: ashan_213@hotmail.com.\"},{\"lastName\":\"Liu\",\"firstName\":\"Zhixin\",\"initials\":\"Z\",\"affiliation\":\"Stats Central, Mark Wainwright Analytical Centre, University of New South Wales, Kensington, NSW, Australia.\"},{\"lastName\":\"Doan\",\"firstName\":\"Paul\",\"initials\":\"P\",\"affiliation\":\"Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.\"},{\"lastName\":\"Haynes\",\"firstName\":\"Anne-Maree\",\"initials\":\"AM\",\"affiliation\":\"Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia.\"},{\"lastName\":\"Delprado\",\"firstName\":\"Warick\",\"initials\":\"W\",\"affiliation\":\"Douglass Hanly Moir Pathology, Sonic Healthcare, St Leonards, NSW, Australia.\"},{\"lastName\":\"Maclean\",\"firstName\":\"Fiona\",\"initials\":\"F\",\"affiliation\":\"Douglass Hanly Moir Pathology, Sonic Healthcare, St Leonards, NSW, Australia; Faculty of Medicine and Health Sciences, Macquarie University, North Ryde, NSW, Australia.\"},{\"lastName\":\"Yuen\",\"firstName\":\"Carlo\",\"initials\":\"C\",\"affiliation\":\"St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.\"},{\"lastName\":\"Stricker\",\"firstName\":\"Phillip\",\"initials\":\"P\",\"affiliation\":\"Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia; Faculty of Medicine, UNSW, Darlinghurst, NSW, Australia.\"},{\"lastName\":\"Thompson\",\"firstName\":\"James\",\"initials\":\"J\",\"affiliation\":\"Department of Urology, St George Hospital, Kogarah, NSW, Australia; Kinghorn Cancer Centre, Garvan Institute, Darlinghurst, NSW, Australia; Faculty of Medicine, UNSW, Darlinghurst, NSW, Australia.\"}],\"journalInfo\":{\"title\":\"Pathology\",\"isoAbbreviation\":\"Pathology\",\"volume\":\"55\",\"issue\":\"4\",\"pages\":\"492-497\",\"publicationDate\":{\"year\":\"2023\",\"month\":\"Jun\"}},\"publicationTypes\":[\"Journal Article\"],\"doi\":\"10.1016/j.pathol.2022.10.012\",\"articleDates\":[{\"dateType\":\"Electronic\",\"year\":\"2023\",\"month\":\"1\",\"day\":\"11\"}],\"meshTerms\":[{\"descriptorName\":\"Male\",\"descriptorUi\":\"D008297\",\"isMajorTopic\":false},{\"descriptorName\":\"Humans\",\"descriptorUi\":\"D006801\",\"isMajorTopic\":false},{\"descriptorName\":\"Prostate\",\"descriptorUi\":\"D011467\",\"qualifierName\":\"pathology\",\"qualifierUi\":\"Q000473\",\"isMajorTopic\":true},{\"descriptorName\":\"Retrospective Studies\",\"descriptorUi\":\"D012189\",\"isMajorTopic\":false},{\"descriptorName\":\"Cohort Studies\",\"descriptorUi\":\"D015331\",\"isMajorTopic\":false},{\"descriptorName\":\"Prospective Studies\",\"descriptorUi\":\"D011446\",\"isMajorTopic\":false},{\"descriptorName\":\"Prostatectomy\",\"descriptorUi\":\"D011468\",\"isMajorTopic\":false},{\"descriptorName\":\"Prostatic Neoplasms\",\"descriptorUi\":\"D011471\",\"qualifierName\":\"surgery\",\"qualifierUi\":\"Q000601\",\"isMajorTopic\":true},{\"descriptorName\":\"Prostate-Specific Antigen\",\"descriptorUi\":\"D017430\",\"isMajorTopic\":false},{\"descriptorName\":\"Neoplasm Recurrence, Local\",\"descriptorUi\":\"D009364\",\"qualifierName\":\"epidemiology\",\"qualifierUi\":\"Q000453\",\"isMajorTopic\":false}]}],\"notFoundPmids\":[],\"eFetchDetails\":{\"urls\":[\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38920407%2C38398155%2C37418998%2C36754722%2C36725447&retmode=xml\"]}}"}],"isError":false}}}],"role":"user"}
{"parts":[{"text":"Summarize some relevant research papers about the best treatments for stage 4 prostate cancer?"}],"role":"user"}
-----------------------------------------------------------
Functions:
pubmed_article_connections: {'sourcePmid': {'description': 'The PubMed Unique Identifier (PMID) of the source article for which to find connections or format citations. This PMID must be a valid number string.', 'pattern': '^\\d+$', 'type': <Type.STRING: 'STRING'>}, 'relationshipType': {'default': 'pubmed_similar_articles', 'description': "Specifies the type of connection or action: 'pubmed_similar_articles' (finds similar articles), 'pubmed_citedin' (finds citing articles), 'pubmed_references' (finds referenced articles), or 'citation_formats' (retrieves formatted citations).", 'enum': ['pubmed_similar_articles', 'pubmed_citedin', 'pubmed_references', 'citation_formats'], 'type': <Type.STRING: 'STRING'>}, 'maxRelatedResults': {'default': 5, 'description': 'Maximum number of related articles to retrieve for relationship-based searches. Default is 5, max is 50.', 'maximum': 50.0, 'type': <Type.INTEGER: 'INTEGER'>}, 'citationStyles': {'default': ['ris'], 'description': "An array of citation styles to format the source article into when 'relationshipType' is 'citation_formats'. Supported styles: 'ris', 'bibtex', 'apa_string', 'mla_string'. Default is ['ris'].", 'items': {'enum': ['ris', 'bibtex', 'apa_string', 'mla_string'], 'type': <Type.STRING: 'STRING'>}, 'type': <Type.ARRAY: 'ARRAY'>}} 
pubmed_fetch_contents: {'pmids': {'description': 'An array of PubMed Unique Identifiers (PMIDs) to fetch. Use this OR queryKey/webEnv.', 'items': {'pattern': '^\\d+$', 'type': <Type.STRING: 'STRING'>}, 'max_items': 200, 'type': <Type.ARRAY: 'ARRAY'>}, 'queryKey': {'description': 'Query key from ESearch history. Requires webEnv. Use this OR pmids.', 'type': <Type.STRING: 'STRING'>}, 'webEnv': {'description': 'Web environment from ESearch history. Requires queryKey. Use this OR pmids.', 'type': <Type.STRING: 'STRING'>}, 'retstart': {'description': '0-based index of the first record to retrieve. Used with queryKey/webEnv.', 'minimum': 0.0, 'type': <Type.INTEGER: 'INTEGER'>}, 'retmax': {'description': 'Maximum number of records to retrieve. Used with queryKey/webEnv.', 'minimum': 1.0, 'type': <Type.INTEGER: 'INTEGER'>}, 'detailLevel': {'default': 'abstract_plus', 'description': "Specifies the level of detail for the fetched content. Options: 'abstract_plus' (parsed details), 'full_xml' (raw PubMedArticle XML), 'medline_text' (MEDLINE format), 'citation_data' (minimal citation data). Defaults to 'abstract_plus'.", 'enum': ['abstract_plus', 'full_xml', 'medline_text', 'citation_data'], 'type': <Type.STRING: 'STRING'>}, 'includeMeshTerms': {'default': True, 'description': "Include MeSH terms in 'abstract_plus' and 'citation_data' results. Default: true.", 'type': <Type.BOOLEAN: 'BOOLEAN'>}, 'includeGrantInfo': {'default': False, 'description': "Include grant info in 'abstract_plus' results. Default: false.", 'type': <Type.BOOLEAN: 'BOOLEAN'>}, 'outputFormat': {'default': 'json', 'description': "Output format. 'json' (default) wraps data in a JSON object. 'raw_text' returns raw text for 'medline_text' or 'full_xml' detail levels.", 'enum': ['json', 'raw_text'], 'type': <Type.STRING: 'STRING'>}} 
pubmed_generate_chart: {'chartType': {'description': 'Specifies the type of chart to generate.', 'enum': ['bar', 'line', 'scatter', 'pie', 'doughnut', 'bubble', 'radar', 'polarArea'], 'type': <Type.STRING: 'STRING'>}, 'title': {'description': 'The main title displayed above the chart.', 'type': <Type.STRING: 'STRING'>}, 'width': {'default': 800, 'description': 'The width of the chart canvas in pixels.', 'type': <Type.INTEGER: 'INTEGER'>}, 'height': {'default': 600, 'description': 'The height of the chart canvas in pixels.', 'type': <Type.INTEGER: 'INTEGER'>}, 'dataValues': {'description': "An array of data objects to plot the chart (e.g., [{ 'year': '2020', 'articles': 150 }]).", 'items': {'type': <Type.OBJECT: 'OBJECT'>}, 'min_items': 1, 'type': <Type.ARRAY: 'ARRAY'>}, 'outputFormat': {'default': 'png', 'description': 'Specifies the output format for the chart.', 'enum': ['png'], 'type': <Type.STRING: 'STRING'>}, 'xField': {'description': 'The field name from `dataValues` for the X-axis.', 'type': <Type.STRING: 'STRING'>}, 'yField': {'description': 'The field name from `dataValues` for the Y-axis.', 'type': <Type.STRING: 'STRING'>}, 'seriesField': {'description': 'The field name for creating multiple data series on the same chart.', 'type': <Type.STRING: 'STRING'>}, 'sizeField': {'description': 'For bubble charts, the field name for encoding bubble size.', 'type': <Type.STRING: 'STRING'>}} 
pubmed_research_agent: {'project_title_suggestion': {'description': 'A concise and descriptive title for the research project.', 'min_length': 5, 'type': <Type.STRING: 'STRING'>}, 'primary_research_goal': {'description': 'The main scientific objective or central question the research aims to address (e.g., "To investigate the role of TREM2 in microglial response to amyloid-beta plaques").', 'min_length': 10, 'type': <Type.STRING: 'STRING'>}, 'research_keywords': {'description': 'Core scientific keywords or MeSH terms defining the research domain (e.g., ["neuroinflammation", "Alzheimer\'s disease", "TREM2"]).', 'items': {'min_length': 1, 'type': <Type.STRING: 'STRING'>}, 'min_items': 1, 'type': <Type.ARRAY: 'ARRAY'>}, 'organism_focus': {'description': 'Primary organism(s) or model systems (e.g., "Homo sapiens (iPSC-derived microglia)", "Mus musculus (5xFAD model)").', 'type': <Type.STRING: 'STRING'>}, 'p1_introduction_and_background': {'description': 'Brief overview of the research area, its significance, and relevant background information leading to this study.', 'type': <Type.STRING: 'STRING'>}, 'p1_specific_research_question': {'description': 'The precise, focused primary research question the study will answer.', 'type': <Type.STRING: 'STRING'>}, 'p1_knowledge_gap': {'description': 'Statement clearly identifying the specific gap in current knowledge this research addresses.', 'type': <Type.STRING: 'STRING'>}, 'p1_primary_hypothesis': {'description': 'The main, testable hypothesis. Should be clear, specific, and falsifiable.', 'type': <Type.STRING: 'STRING'>}, 'p1_secondary_questions_or_hypotheses': {'description': 'Any secondary questions or hypotheses to be explored.', 'items': {'type': <Type.STRING: 'STRING'>}, 'type': <Type.ARRAY: 'ARRAY'>}, 'p1_pubmed_search_strategy_description': {'description': 'Description of the primary literature search strategy (e.g., for PubMed), including key terms and database considerations.', 'type': <Type.STRING: 'STRING'>}, 'p1_literature_review_scope': {'description': 'The defined scope for the literature review (e.g., timeframes, study types, key themes).', 'type': <Type.STRING: 'STRING'>}, 'p1_lit_review_databases_and_approach': {'description': 'Key databases (e.g., PubMed, EMBASE) and the search approach (e.g., iterative queries, snowballing).', 'type': <Type.STRING: 'STRING'>}, 'p1_experimental_paradigm': {'description': "The overarching experimental design or study type (e.g., 'comparative multi-omics analysis', 'longitudinal cohort study').", 'type': <Type.STRING: 'STRING'>}, 'p1_data_acquisition_plan_existing_data': {'description': 'Strategy for identifying and retrieving relevant existing datasets (databases, data types, tools).', 'type': <Type.STRING: 'STRING'>}, 'p1_data_acquisition_plan_new_data': {'description': 'Plan for generating novel data (data types, experimental models, key procedures, deposition plan).', 'type': <Type.STRING: 'STRING'>}, 'p1_blast_utilization_plan': {'description': 'If applicable, how sequence alignment services (e.g., NCBI BLAST) will be used (purpose, programs, databases).', 'type': <Type.STRING: 'STRING'>}, 'p1_controls_and_rigor': {'description': 'Description of key experimental controls and measures to ensure scientific rigor and reproducibility.', 'type': <Type.STRING: 'STRING'>}, 'p1_methodological_challenges_and_mitigation': {'description': 'Anticipated methodological challenges and proposed mitigation strategies.', 'type': <Type.STRING: 'STRING'>}, 'p2_data_collection_methods_wet_lab': {'description': 'Specific wet-lab protocols if new data is generated (sample prep, treatments, instruments).', 'type': <Type.STRING: 'STRING'>}, 'p2_data_collection_methods_dry_lab': {'description': 'Execution details for data retrieval from databases (queries, tools, accessioning).', 'type': <Type.STRING: 'STRING'>}, 'p2_data_preprocessing_and_qc_plan': {'description': 'Pipeline for data cleaning, preprocessing (e.g., alignment, normalization), and quality control (metrics, thresholds, tools).', 'type': <Type.STRING: 'STRING'>}, 'p3_data_analysis_strategy': {'description': 'Core statistical and computational methods to analyze data and test hypotheses (tests, software, ML models if any).', 'type': <Type.STRING: 'STRING'>}, 'p3_bioinformatics_pipeline_summary': {'description': 'Summary of the bioinformatics pipeline for high-throughput data analysis (tools, downstream analyses).', 'type': <Type.STRING: 'STRING'>}, 'p3_results_interpretation_framework': {'description': 'Framework for evaluating findings against hypotheses (statistical significance, biological relevance).', 'type': <Type.STRING: 'STRING'>}, 'p3_comparison_with_literature_plan': {'description': 'Strategy for contextualizing results with existing literature and addressing discrepancies.', 'type': <Type.STRING: 'STRING'>}, 'p4_dissemination_manuscript_plan': {'description': 'Plan for manuscript preparation (core message, target journal profile, key figures).', 'type': <Type.STRING: 'STRING'>}, 'p4_dissemination_data_deposition_plan': {'description': 'Strategy for depositing data in public repositories (types, repositories, FAIR principles).', 'type': <Type.STRING: 'STRING'>}, 'p4_peer_review_and_publication_approach': {'description': 'Approach to journal submission and addressing peer review.', 'type': <Type.STRING: 'STRING'>}, 'p4_future_research_directions': {'description': 'Potential next steps, new questions, or translational applications arising from the research.', 'type': <Type.STRING: 'STRING'>}, 'cc_record_keeping_and_data_management': {'description': 'Plan for record-keeping, version control, data storage, and DMP.', 'type': <Type.STRING: 'STRING'>}, 'cc_collaboration_strategy': {'description': 'If applicable, strategy for collaboration, communication, roles, and authorship.', 'type': <Type.STRING: 'STRING'>}, 'cc_ethical_considerations': {'description': 'Ethical considerations, IRB/IACUC approval plans, data privacy, RCR training.', 'type': <Type.STRING: 'STRING'>}, 'include_detailed_prompts_for_agent': {'default': False, 'description': 'If true, the tool will add more detailed instructive prompts/guidance within the output fields for a research agent. If false (default), it will primarily structure the provided inputs with minimal additional prompting.', 'type': <Type.BOOLEAN: 'BOOLEAN'>}} 
pubmed_search_articles: {'queryTerm': {'description': 'The primary keyword or phrase to search for in PubMed. Must be at least 3 characters long.', 'min_length': 3, 'type': <Type.STRING: 'STRING'>}, 'maxResults': {'default': 20, 'description': "Maximum number of articles to retrieve. Corresponds to ESearch's 'retmax' parameter. Default is 20, max is 1000.", 'maximum': 1000.0, 'type': <Type.INTEGER: 'INTEGER'>}, 'sortBy': {'default': 'relevance', 'description': "Sorting criteria for results. Options: 'relevance' (default), 'pub_date', 'author', 'journal_name'.", 'enum': ['relevance', 'pub_date', 'author', 'journal_name'], 'type': <Type.STRING: 'STRING'>}, 'dateRange': {'description': 'Defines an optional date range for the search.', 'properties': {'minDate': {'description': 'The start date for the search range (YYYY, YYYY/MM, or YYYY/MM/DD).', 'pattern': '^\\d{4}(\\/\\d{2}(\\/\\d{2})?)?$', 'type': <Type.STRING: 'STRING'>}, 'maxDate': {'description': 'The end date for the search range (YYYY, YYYY/MM, or YYYY/MM/DD).', 'pattern': '^\\d{4}(\\/\\d{2}(\\/\\d{2})?)?$', 'type': <Type.STRING: 'STRING'>}, 'dateType': {'default': 'pdat', 'description': "The type of date to filter by: 'pdat' (Publication Date), 'mdat' (Modification Date), 'edat' (Entrez Date). Default is 'pdat'.", 'enum': ['pdat', 'mdat', 'edat'], 'type': <Type.STRING: 'STRING'>}}, 'type': <Type.OBJECT: 'OBJECT'>}, 'filterByPublicationTypes': {'description': 'An array of publication types to filter by (e.g., ["Review", "Clinical Trial"]).', 'items': {'type': <Type.STRING: 'STRING'>}, 'type': <Type.ARRAY: 'ARRAY'>}, 'fetchBriefSummaries': {'default': 0, 'description': 'Number of top PMIDs for which to fetch brief summaries using ESummary. Set to 0 to disable. Max 50. Default 0.', 'maximum': 50.0, 'minimum': 0.0, 'type': <Type.INTEGER: 'INTEGER'>}} 
-----------------------------------------------------------

google_llm.py:219 INFO:Response received from the model.
google_llm.py:220 DEBUG:
LLM Response:
-----------------------------------------------------------
Text:
The research papers found discuss various aspects of advanced prostate cancer treatment, with a focus on biochemical recurrence, salvage therapy, and risk stratification. Here's a summary of the findings:

**1. Management of Biochemical Recurrence (BCR) in Prostate Cancer:**
This paper emphasizes the heterogeneity of BCR and the need for personalized management. It suggests using new-generation imaging like PSMA PET/CT to detect low-volume metastases. For low-risk BCR, active observation is recommended. High-risk BCR patients (defined by PSA doubling time ≤ 9 months) benefit from early systemic therapy. The EMBARK study showed that combining enzalutamide with leuprolide improves metastasis-free survival compared to leuprolide alone, without compromising quality of life in the asymptomatic phase. The study also explored the use of enzalutamide alone, suggesting potential benefits but with less evidence than combination therapy. Real-world data is needed to validate these findings.
*   **Citation:** Sciarra, A., Santarelli, V., Salciccia, S., Moriconi, M., Basile, G., Santodirocco, L., Carino, D., Frisenda, M., Di Pierro, G., Del Giudice, F., Gentilucci, A., & Bevilacqua, G. (2024). How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. *Cancers*, *16*(4), 764.
*   **Link:** https://pubmed.ncbi.nlm.nih.gov/38398155/

**2. Advances in High-Risk Localized Prostate Cancer:**
This review focuses on staging and management of high-risk localized prostate cancer. It highlights the importance of accurate staging using tools like PSMA PET/CT and nomograms to guide treatment decisions. While there's ongoing debate about the best local treatment, the review emphasizes tailoring therapy to individual patient profiles and suggests that multimodal treatment may offer superior outcomes.
*   **Citation:** Reina, Y., Villaquirán, C., & García-Perdomo, H. A. (2023). Advances in high-risk localized prostate cancer: Staging and management. *Current Problems in Cancer*, *47*(4), 100993.
*   **Link:** https://pubmed.ncbi.nlm.nih.gov/37418998/

**3. Salvage Stereotactic Radiation Therapy for Intraprostatic Tumor Recurrence:**
This paper presents the phase 1 results of a study evaluating salvage stereotactic radiation therapy (SBRT) for prostate cancer recurrence after previous external radiation. The study aimed to determine the optimal dose regimen. A dose of 6 fractions of 6 Gy was found to be safe and tolerable, with acceptable acute toxicity. While the follow-up period was short, no late grade >2 genitourinary or gastrointestinal toxicity was reported, and all patients remained relapse-free. This dose regimen was selected for further phase 2 study.
*   **Citation:** Pasquier, D., Lacornerie, T., Supiot, S., Pommier, P., Quivrin, M., Simon, J. M., Loos, G., Meyer, E., Calais, G., Peiffert, D., Vandendorpe, B., Aymes, E., Leguillette, C., Brihoum, M., Nenan, S., Cormier, L., Le Deley, M. C., & Lartigau, E. F. (2023). The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. *European Urology Oncology*, *6*(4), 399-405.
*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36754722/

**4. Index Grade Group vs. Composite Grade Group for Predicting BCR:**
This study investigated whether the index grade group (highest grade lesion) or composite grade group (overall grade of all tumors) is a better predictor of biochemical recurrence (BCR) after radical prostatectomy. The findings indicate that the index grade group is superior. In cases where the index and composite grades were discordant, a higher index grade group was associated with increased BCR rates. The study recommends using the index grade group for post-operative counseling regarding prognosis and follow-up.
*   **Citation:** Best, O., Canagasingham, A., Liu, Z., Doan, P., Haynes, A. M., Delprado, W., Maclean, F., Yuen, C., Stricker, P., & Thompson, J. (2023). Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. *Pathology*, *55*(4), 492-497.
*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36725447/

**Note:** The first paper, "A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)," appears to be about a different type of cancer (advanced solid tumors and clear cell renal cell carcinoma) and not specifically prostate cancer. Therefore, it has not been included in the summary above.
-----------------------------------------------------------
Function calls:

-----------------------------------------------------------
Raw response:
{"sdk_http_response":{"headers":{"Content-Type":"application/json; charset=UTF-8","Vary":"Origin, X-Origin, Referer","Content-Encoding":"gzip","Date":"Mon, 01 Dec 2025 05:07:27 GMT","Server":"scaffolding on HTTPServer2","X-XSS-Protection":"0","X-Frame-Options":"SAMEORIGIN","X-Content-Type-Options":"nosniff","Server-Timing":"gfet4t7; dur=7218","Alt-Svc":"h3=\":443\"; ma=2592000,h3-29=\":443\"; ma=2592000","Transfer-Encoding":"chunked"}},"candidates":[{"content":{"parts":[{"text":"The research papers found discuss various aspects of advanced prostate cancer treatment, with a focus on biochemical recurrence, salvage therapy, and risk stratification. Here's a summary of the findings:\n\n**1. Management of Biochemical Recurrence (BCR) in Prostate Cancer:**\nThis paper emphasizes the heterogeneity of BCR and the need for personalized management. It suggests using new-generation imaging like PSMA PET/CT to detect low-volume metastases. For low-risk BCR, active observation is recommended. High-risk BCR patients (defined by PSA doubling time ≤ 9 months) benefit from early systemic therapy. The EMBARK study showed that combining enzalutamide with leuprolide improves metastasis-free survival compared to leuprolide alone, without compromising quality of life in the asymptomatic phase. The study also explored the use of enzalutamide alone, suggesting potential benefits but with less evidence than combination therapy. Real-world data is needed to validate these findings.\n*   **Citation:** Sciarra, A., Santarelli, V., Salciccia, S., Moriconi, M., Basile, G., Santodirocco, L., Carino, D., Frisenda, M., Di Pierro, G., Del Giudice, F., Gentilucci, A., & Bevilacqua, G. (2024). How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. *Cancers*, *16*(4), 764.\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/38398155/\n\n**2. Advances in High-Risk Localized Prostate Cancer:**\nThis review focuses on staging and management of high-risk localized prostate cancer. It highlights the importance of accurate staging using tools like PSMA PET/CT and nomograms to guide treatment decisions. While there's ongoing debate about the best local treatment, the review emphasizes tailoring therapy to individual patient profiles and suggests that multimodal treatment may offer superior outcomes.\n*   **Citation:** Reina, Y., Villaquirán, C., & García-Perdomo, H. A. (2023). Advances in high-risk localized prostate cancer: Staging and management. *Current Problems in Cancer*, *47*(4), 100993.\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/37418998/\n\n**3. Salvage Stereotactic Radiation Therapy for Intraprostatic Tumor Recurrence:**\nThis paper presents the phase 1 results of a study evaluating salvage stereotactic radiation therapy (SBRT) for prostate cancer recurrence after previous external radiation. The study aimed to determine the optimal dose regimen. A dose of 6 fractions of 6 Gy was found to be safe and tolerable, with acceptable acute toxicity. While the follow-up period was short, no late grade >2 genitourinary or gastrointestinal toxicity was reported, and all patients remained relapse-free. This dose regimen was selected for further phase 2 study.\n*   **Citation:** Pasquier, D., Lacornerie, T., Supiot, S., Pommier, P., Quivrin, M., Simon, J. M., Loos, G., Meyer, E., Calais, G., Peiffert, D., Vandendorpe, B., Aymes, E., Leguillette, C., Brihoum, M., Nenan, S., Cormier, L., Le Deley, M. C., & Lartigau, E. F. (2023). The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. *European Urology Oncology*, *6*(4), 399-405.\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36754722/\n\n**4. Index Grade Group vs. Composite Grade Group for Predicting BCR:**\nThis study investigated whether the index grade group (highest grade lesion) or composite grade group (overall grade of all tumors) is a better predictor of biochemical recurrence (BCR) after radical prostatectomy. The findings indicate that the index grade group is superior. In cases where the index and composite grades were discordant, a higher index grade group was associated with increased BCR rates. The study recommends using the index grade group for post-operative counseling regarding prognosis and follow-up.\n*   **Citation:** Best, O., Canagasingham, A., Liu, Z., Doan, P., Haynes, A. M., Delprado, W., Maclean, F., Yuen, C., Stricker, P., & Thompson, J. (2023). Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. *Pathology*, *55*(4), 492-497.\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36725447/\n\n**Note:** The first paper, \"A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170),\" appears to be about a different type of cancer (advanced solid tumors and clear cell renal cell carcinoma) and not specifically prostate cancer. Therefore, it has not been included in the summary above."}],"role":"model"},"finish_reason":"STOP","index":0}],"model_version":"gemini-2.5-flash-lite","response_id":"jyItad6pIeLXjMcP7a2d0Ag","usage_metadata":{"cache_tokens_details":[{"modality":"TEXT","token_count":10870}],"cached_content_token_count":10870,"candidates_token_count":1180,"prompt_token_count":11587,"prompt_tokens_details":[{"modality":"TEXT","token_count":11587}],"total_token_count":12767}}
-----------------------------------------------------------

base_authenticated_tool.py:72 DEBUG:auth_config or auth_config.auth_scheme is missing, so authentication will be skipped.
base_authenticated_tool.py:72 DEBUG:auth_config or auth_config.auth_scheme is missing, so authentication will be skipped.
base_authenticated_tool.py:72 DEBUG:auth_config or auth_config.auth_scheme is missing, so authentication will be skipped.
base_authenticated_tool.py:72 DEBUG:auth_config or auth_config.auth_scheme is missing, so authentication will be skipped.
base_authenticated_tool.py:72 DEBUG:auth_config or auth_config.auth_scheme is missing, so authentication will be skipped.
core.py:104 DEBUG:executing functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112cfe540>, 'SELECT sessions.app_name AS sessions_app_name, sessions.user_id AS sessions_user_id, sessions.id AS sessions_id, sessions.state AS sessions_state, sessions.create_time AS sessions_create_time, sessions.update_time AS sessions_update_time \nFROM sessions \nWHERE sessions.app_name = ? AND sessions.user_id = ? AND sessions.id = ?', ('default', 'default', 'conversation-06'))
core.py:106 DEBUG:operation functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112cfe540>, 'SELECT sessions.app_name AS sessions_app_name, sessions.user_id AS sessions_user_id, sessions.id AS sessions_id, sessions.state AS sessions_state, sessions.create_time AS sessions_create_time, sessions.update_time AS sessions_update_time \nFROM sessions \nWHERE sessions.app_name = ? AND sessions.user_id = ? AND sessions.id = ?', ('default', 'default', 'conversation-06')) completed
core.py:104 DEBUG:executing functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112cfe540>)
core.py:106 DEBUG:operation functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112cfe540>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method close of sqlite3.Cursor object at 0x112cfe540>)
core.py:106 DEBUG:operation functools.partial(<built-in method close of sqlite3.Cursor object at 0x112cfe540>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'SELECT app_states.app_name AS app_states_app_name, app_states.state AS app_states_state, app_states.update_time AS app_states_update_time \nFROM app_states \nWHERE app_states.app_name = ?', ('default',))
core.py:106 DEBUG:operation functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'SELECT app_states.app_name AS app_states_app_name, app_states.state AS app_states_state, app_states.update_time AS app_states_update_time \nFROM app_states \nWHERE app_states.app_name = ?', ('default',)) completed
core.py:104 DEBUG:executing functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112c967c0>)
core.py:106 DEBUG:operation functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112c967c0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>)
core.py:106 DEBUG:operation functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'SELECT user_states.app_name AS user_states_app_name, user_states.user_id AS user_states_user_id, user_states.state AS user_states_state, user_states.update_time AS user_states_update_time \nFROM user_states \nWHERE user_states.app_name = ? AND user_states.user_id = ?', ('default', 'default'))
core.py:106 DEBUG:operation functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'SELECT user_states.app_name AS user_states_app_name, user_states.user_id AS user_states_user_id, user_states.state AS user_states_state, user_states.update_time AS user_states_update_time \nFROM user_states \nWHERE user_states.app_name = ? AND user_states.user_id = ?', ('default', 'default')) completed
core.py:104 DEBUG:executing functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112c967c0>)
core.py:106 DEBUG:operation functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112c967c0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>)
core.py:106 DEBUG:operation functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'INSERT INTO events (id, app_name, user_id, session_id, invocation_id, author, actions, long_running_tool_ids_json, branch, timestamp, content, grounding_metadata, custom_metadata, usage_metadata, citation_metadata, partial, turn_complete, error_code, error_message, interrupted, input_transcription, output_transcription) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)', ('ae02d7b8-f1a6-4aa5-a543-f3c4d989c8ad', 'default', 'default', 'conversation-06', 'e-18091518-8dde-41ba-857c-a1e3e5af16f9', 'research_paper_finder_agent', <memory at 0x112b4d480>, None, None, '2025-11-30 21:07:20.265784', '{"parts": [{"text": "The research papers found discuss various aspects of advanced prostate cancer treatment, with a focus on biochemical recurrence, salvage therapy, and risk stratification. Here\'s a summary of the findings:\\n\\n**1. Management of Biochemical Recurrence (BCR) in Prostate Cancer:**\\nThis paper emphasizes the heterogeneity of BCR and the need for personalized management. It suggests using new-generation imaging like PSMA PET/CT to detect low-volume metastases. For low-risk BCR, active observation is recommended. High-risk BCR patients (defined by PSA doubling time \\u2264 9 months) benefit from early systemic therapy. The EMBARK study showed that combining enzalutamide with leuprolide improves metastasis-free survival compared to leuprolide alone, without compromising quality of life in the asymptomatic phase. The study also explored the use of enzalutamide alone, suggesting potential benefits but with less evidence than combination therapy. Real-world data is needed to validate these findings.\\n*   **Citation:** Sciarra, A., Santarelli, V., Salciccia, S., Moriconi, M., Basile, G., Santodirocco, L., Carino, D., Frisenda, M., Di Pierro, G., Del Giudice, F., Gentilucci, A., & Bevilacqua, G. (2024). How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. *Cancers*, *16*(4), 764.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/38398155/\\n\\n**2. Advances in High-Risk Localized Prostate Cancer:**\\nThis review focuses on staging and management of high-risk localized prostate cancer. It highlights the importance of accurate staging using tools like PSMA PET/CT and nomograms to guide treatment decisions. While there\'s ongoing debate about the best local treatment, the review emphasizes tailoring therapy to individual patient profiles and suggests that multimodal treatment may offer superior outcomes.\\n*   **Citation:** Reina, Y., Villaquir\\u00e1n, C., & Garc\\u00eda-Perdomo, H. A. (2023). Advances in high-risk localized prostate cancer: Staging and management. *Current Problems in Cancer*, *47*(4), 100993.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/37418998/\\n\\n**3. Salvage Stereotactic Radiation Therapy for Intraprostatic Tumor Recurrence:**\\nThis paper presents the phase 1 results of a study evaluating salvage stereotactic radiation therapy (SBRT) for prostate cancer recurrence after previous external radiation. The study aimed to determine the optimal dose regimen. A dose of 6 fractions of 6 Gy was found to be safe and tolerable, with acceptable acute toxicity. While the follow-up period was short, no late grade >2 genitourinary or gastrointestinal toxicity was reported, and all patients remained relapse-free. This dose regimen was selected for further phase 2 study.\\n*   **Citation:** Pasquier, D., Lacornerie, T., Supiot, S., Pommier, P., Quivrin, M., Simon, J. M., Loos, G., Meyer, E., Calais, G., Peiffert, D., Vandendorpe, B., Aymes, E., Leguillette, C., Brihoum, M., Nenan, S., Cormier, L., Le Deley, M. C., & Lartigau, E. F. (2023). The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. *European Urology Oncology*, *6*(4), 399-405.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36754722/\\n\\n**4. Index Grade Group vs. Composite Grade Group for Predicting BCR:**\\nThis study investigated whether the index grade group (highest grade lesion) or composite grade group (overall grade of all tumors) is a better predictor of biochemical recurrence (BCR) after radical prostatectomy. The findings indicate that the index grade group is superior. In cases where the index and composite grades were discordant, a higher index grade group was associated with increased BCR rates. The study recommends using the index grade group for post-operative counseling regarding prognosis and follow-up.\\n*   **Citation:** Best, O., Canagasingham, A., Liu, Z., Doan, P., Haynes, A. M., Delprado, W., Maclean, F., Yuen, C., Stricker, P., & Thompson, J. (2023). Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. *Pathology*, *55*(4), 492-497.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36725447/\\n\\n**Note:** The first paper, \\"A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170),\\" appears to be about a different type of cancer (advanced solid tumors and clear cell renal cell carcinoma) and not specifically prostate cancer. Therefore, it has not been included in the summary above."}], "role": "model"}', None, None, '{"cache_tokens_details": [{"modality": "TEXT", "token_count": 10870}], "cached_content_token_count": 10870, "candidates_token_count": 1180, "prompt_token_count": 11587, "prompt_tokens_details": [{"modality": "TEXT", "token_count": 11587}], "total_token_count": 12767}', None, None, None, None, None, None, None, None))
core.py:106 DEBUG:operation functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112c967c0>, 'INSERT INTO events (id, app_name, user_id, session_id, invocation_id, author, actions, long_running_tool_ids_json, branch, timestamp, content, grounding_metadata, custom_metadata, usage_metadata, citation_metadata, partial, turn_complete, error_code, error_message, interrupted, input_transcription, output_transcription) VALUES (?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?)', ('ae02d7b8-f1a6-4aa5-a543-f3c4d989c8ad', 'default', 'default', 'conversation-06', 'e-18091518-8dde-41ba-857c-a1e3e5af16f9', 'research_paper_finder_agent', <memory at 0x112b4d480>, None, None, '2025-11-30 21:07:20.265784', '{"parts": [{"text": "The research papers found discuss various aspects of advanced prostate cancer treatment, with a focus on biochemical recurrence, salvage therapy, and risk stratification. Here\'s a summary of the findings:\\n\\n**1. Management of Biochemical Recurrence (BCR) in Prostate Cancer:**\\nThis paper emphasizes the heterogeneity of BCR and the need for personalized management. It suggests using new-generation imaging like PSMA PET/CT to detect low-volume metastases. For low-risk BCR, active observation is recommended. High-risk BCR patients (defined by PSA doubling time \\u2264 9 months) benefit from early systemic therapy. The EMBARK study showed that combining enzalutamide with leuprolide improves metastasis-free survival compared to leuprolide alone, without compromising quality of life in the asymptomatic phase. The study also explored the use of enzalutamide alone, suggesting potential benefits but with less evidence than combination therapy. Real-world data is needed to validate these findings.\\n*   **Citation:** Sciarra, A., Santarelli, V., Salciccia, S., Moriconi, M., Basile, G., Santodirocco, L., Carino, D., Frisenda, M., Di Pierro, G., Del Giudice, F., Gentilucci, A., & Bevilacqua, G. (2024). How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. *Cancers*, *16*(4), 764.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/38398155/\\n\\n**2. Advances in High-Risk Localized Prostate Cancer:**\\nThis review focuses on staging and management of high-risk localized prostate cancer. It highlights the importance of accurate staging using tools like PSMA PET/CT and nomograms to guide treatment decisions. While there\'s ongoing debate about the best local treatment, the review emphasizes tailoring therapy to individual patient profiles and suggests that multimodal treatment may offer superior outcomes.\\n*   **Citation:** Reina, Y., Villaquir\\u00e1n, C., & Garc\\u00eda-Perdomo, H. A. (2023). Advances in high-risk localized prostate cancer: Staging and management. *Current Problems in Cancer*, *47*(4), 100993.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/37418998/\\n\\n**3. Salvage Stereotactic Radiation Therapy for Intraprostatic Tumor Recurrence:**\\nThis paper presents the phase 1 results of a study evaluating salvage stereotactic radiation therapy (SBRT) for prostate cancer recurrence after previous external radiation. The study aimed to determine the optimal dose regimen. A dose of 6 fractions of 6 Gy was found to be safe and tolerable, with acceptable acute toxicity. While the follow-up period was short, no late grade >2 genitourinary or gastrointestinal toxicity was reported, and all patients remained relapse-free. This dose regimen was selected for further phase 2 study.\\n*   **Citation:** Pasquier, D., Lacornerie, T., Supiot, S., Pommier, P., Quivrin, M., Simon, J. M., Loos, G., Meyer, E., Calais, G., Peiffert, D., Vandendorpe, B., Aymes, E., Leguillette, C., Brihoum, M., Nenan, S., Cormier, L., Le Deley, M. C., & Lartigau, E. F. (2023). The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study. *European Urology Oncology*, *6*(4), 399-405.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36754722/\\n\\n**4. Index Grade Group vs. Composite Grade Group for Predicting BCR:**\\nThis study investigated whether the index grade group (highest grade lesion) or composite grade group (overall grade of all tumors) is a better predictor of biochemical recurrence (BCR) after radical prostatectomy. The findings indicate that the index grade group is superior. In cases where the index and composite grades were discordant, a higher index grade group was associated with increased BCR rates. The study recommends using the index grade group for post-operative counseling regarding prognosis and follow-up.\\n*   **Citation:** Best, O., Canagasingham, A., Liu, Z., Doan, P., Haynes, A. M., Delprado, W., Maclean, F., Yuen, C., Stricker, P., & Thompson, J. (2023). Index grade group is superior to composite grade group for prediction of biochemical recurrence following radical prostatectomy. *Pathology*, *55*(4), 492-497.\\n*   **Link:** https://pubmed.ncbi.nlm.nih.gov/36725447/\\n\\n**Note:** The first paper, \\"A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170),\\" appears to be about a different type of cancer (advanced solid tumors and clear cell renal cell carcinoma) and not specifically prostate cancer. Therefore, it has not been included in the summary above."}], "role": "model"}', None, None, '{"cache_tokens_details": [{"modality": "TEXT", "token_count": 10870}], "cached_content_token_count": 10870, "candidates_token_count": 1180, "prompt_token_count": 11587, "prompt_tokens_details": [{"modality": "TEXT", "token_count": 11587}], "total_token_count": 12767}', None, None, None, None, None, None, None, None)) completed
core.py:104 DEBUG:executing functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>)
core.py:106 DEBUG:operation functools.partial(<built-in method close of sqlite3.Cursor object at 0x112c967c0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method commit of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method commit of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method cursor of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112cfc640>, 'SELECT sessions.app_name, sessions.user_id, sessions.id, sessions.state, sessions.create_time, sessions.update_time \nFROM sessions \nWHERE sessions.app_name = ? AND sessions.user_id = ? AND sessions.id = ?', ('default', 'default', 'conversation-06'))
core.py:106 DEBUG:operation functools.partial(<built-in method execute of sqlite3.Cursor object at 0x112cfc640>, 'SELECT sessions.app_name, sessions.user_id, sessions.id, sessions.state, sessions.create_time, sessions.update_time \nFROM sessions \nWHERE sessions.app_name = ? AND sessions.user_id = ? AND sessions.id = ?', ('default', 'default', 'conversation-06')) completed
core.py:104 DEBUG:executing functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112cfc640>)
core.py:106 DEBUG:operation functools.partial(<built-in method fetchall of sqlite3.Cursor object at 0x112cfc640>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method close of sqlite3.Cursor object at 0x112cfc640>)
core.py:106 DEBUG:operation functools.partial(<built-in method close of sqlite3.Cursor object at 0x112cfc640>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>) completed
core.py:104 DEBUG:executing functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>)
core.py:106 DEBUG:operation functools.partial(<built-in method rollback of sqlite3.Connection object at 0x112bff3d0>) completed
